About Acarix

Innovative technology based on pioneering research

Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.

Referring symptomatic patients to the right investigation method
Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient.

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor® system is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than 10 minutes with 97% confidence. Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).

“At Acarix, we are committed to making the rule-out of patients with symptoms of significant CAD easier, quicker and more reliable for all healthcare professionals.”

References
1. Therming, C. et al. Low Diagnostic Yield of Non-Invasive Testing in Patients with Suspected Coronary Artery Disease: Results From a Large Unselected Hospital-Based Sample. Eur Heart J – Qual Care Clin Outcomes 2018: 4, 301-308
2. Winther, S. et al. Diagnostic performance of an acoustic-based system for coronary artery disease risk stratification. Heart 2018: 104, 928-935.
3. Douglas PM et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med 2015: 372, 1291-1300
4. Schmidt S et al. Coronary artery disease risk reclassification by a new acoustic‑based score. Int J Cardiovasc Imaging 2019: 35, 2019–2028.